Literature DB >> 12731453

Anticonvulsant action of celecoxib (alone and in combination with sub-threshold dose of phenytoin) in electroshock induced convulsion.

N Shafiq1, S Malhotra, P Pandhi.   

Abstract

Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor, COX-2 has been shown to be upregulated by convulsive nerve activity. Various earlier studies have given conflicting reports on the effect of COX inhibitors on seizures. This study investigates the effect of pretreatment with celecoxib alone, or in combination with phenytoin, on electroshock-induced convulsions. Both percentage protection (i.e., the percentage of animals not showing Tonic Hind Limb Extension [THLE] when a fixed dose of current is administered) and CC50 (i.e., the threshold current inducing THLE in 50%) was determined using a technoconvulsometer. Celecoxib and phenytoin were administered 1 and 2 h, respectively, prior to the experiments. When administered alone, celecoxib showed an increase in percentage protection at increasing doses, with maximum percentage protection (66.6%) occurring at a 30 mg/kg-1 dose. The ED25 value of celecoxib was calculated to be 8.03 mg/kg-1. The CC50 values for the treatment groups were significantly increased compared with the control group (CC50 values for control, celecoxib 10 mg/kg-1, celecoxib 20 mg/kg-1 and celecoxib 30 mg/kg-1, respectively, were 36.3, 49.12, 100.3 and 125.02 mA). An increase in percentage protection was noted when celecoxib 8.03 mg/kg-1 was coadministered with phenytoin 6 mg/kg-1 (66.6% with the combination vs. 16.6% when administered individually). A significant increase was noted in the CC50 value in a combination regimen (CC50 = 79.06) compared with either drug administered alone (CC50 = 49.12 with celecoxib 8.03 mg/kg-1 and 62.06 with phenytoin 6 mg/kg-1). This study may stimulate further interest in the role of COX-2 inhibitors in the modulation of seizure activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12731453     DOI: 10.1358/mf.2003.25.2.723681

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  6 in total

Review 1.  Role of oxidative stress in epileptic seizures.

Authors:  Eun-Joo Shin; Ji Hoon Jeong; Yoon Hee Chung; Won-Ki Kim; Kwang-Ho Ko; Jae-Hyung Bach; Jau-Shyong Hong; Yukio Yoneda; Hyoung-Chun Kim
Journal:  Neurochem Int       Date:  2011-06-13       Impact factor: 3.921

Review 2.  Novel therapeutic approaches for disease-modification of epileptogenesis for curing epilepsy.

Authors:  Bryan L Clossen; Doodipala Samba Reddy
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-02-05       Impact factor: 5.187

3.  Cyclooxygenase-2 inhibitor inhibits hippocampal synaptic reorganization in pilocarpine-induced status epilepticus rats.

Authors:  Hai-Ju Zhang; Ruo-Peng Sun; Ge-Fei Lei; Lu Yang; Chun-Xi Liu
Journal:  J Zhejiang Univ Sci B       Date:  2008-11       Impact factor: 3.066

4.  A COX/5-LOX Inhibitor Licofelone Revealed Anticonvulsant Properties Through iNOS Diminution in Mice.

Authors:  Borna Payandemehr; Mahsima Khoshneviszadeh; Bardia Varastehmoradi; Ramtin Gholizadeh; Taraneh Bahremand; Hossein Attar; Arash Bahremand; Ahmad Reza Dehpour
Journal:  Neurochem Res       Date:  2015-07-28       Impact factor: 3.996

Review 5.  Recent treatment advances and novel therapeutic approaches in epilepsy.

Authors:  Enrique Serrano; Andres M Kanner
Journal:  F1000Prime Rep       Date:  2015-05-26

Review 6.  From the Molecular Mechanism to Pre-clinical Results: Anti-epileptic Effects of Fingolimod.

Authors:  Yam Nath Paudel; Efthalia Angelopoulou; Christina Piperi; Vadym Gnatkovsky; Iekhsan Othman; Mohd Farooq Shaikh
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.